Enzymotec Ltd. Initiates Clinical Study Of Vayarin In Adult ADHD

Enzymotec Ltd., (Nasdaq: ENZY), a developer, manufacturer, and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced the initiation of a clinical study to evaluate the efficacy of Vayarin® in adults with Attention Deficit Hyperactivity Disorder, or ADHD."The initiation of this study is an important milestone for Enzymotec as we focus on expanding the target population that can benefit from Vayarin beyond the current indication for children. The high risk of abuse is a critical factor when trying to manage ADHD in the adult population. The fact that Vayarin is considered safe, with no addictive side effects, represents a tremendous advantage in the management of ADHD," stated Robert Crim, CEO of VAYA Pharma, a division of Enzymotec Ltd.The randomized, double-blind, placebo-controlled study will enroll 171 patients between the ages of eighteen and fifty-five. This will be a multi-center study in the United States, including the NYU School of Medicine (Dr. Lenard Adler, PI). The study was designed to assess the efficacy of Vayarin in adults with ADHD, measured primarily by the ADHD Investigator Symptom Rating Scale (AISRS)."Vayarin has been clinically shown to be safe and effective for the management of ADHD in children. We hope this study will validate the benefits of Vayarin in adults with ADHD," commented Dr. Yael Richter, Head of VAYA Pharma Research Center at Enzymotec. "Vayarin is a unique lipid composition specifically designed to manage certain lipid imbalances associated with this lifelong neurodevelopmental disorder that tends to persist into adulthood. Approximately 60 percent of children with ADHD carry the disorder into adulthood. This translates into approximately 4 percent of the adult population, or 8 million adults in the United States, which creates a large opportunity for Enzymotec."